DNAzyme-based therapeutics for cancer treatment

摘要: Gene-silencing strategies based on catalytic nucleic acids have been rapidly developed in the past decades. Ribozymes, antisense oligonucleotides and RNA interference actively pursued for years due to their potential application gene inactivation. Pioneered by Joyce et al., a new class of acid composed deoxyribonucleotides has emerged via an vitro selection system. The therapeutic these RNA-cleaving DNAzymes shown both vivo. Although they rival activity stability synthetic ribozymes, are limited inefficient delivery intracellular targets. Recent successes clinical testing cancer patients revitalized utility DNAzymes.